Pantoprazole DR
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Defense Logistics Agency (DLA) intends to issue a solicitation for a national requirements contract for Pantoprazole DR Tablets, specifically 40 mg tablets available in 90 and 1000 count bottles and 20 mg tablets in 90 count bottles. This acquisition will be unrestricted, fully competitive, and established as a firm-fixed price, requirements-type contract with a one-year base period and four one-year option periods. The contract aims to establish a national supply source for these commercial items to be used by Department of Defense customers via the DLA prime vendor program, with estimated annual usage provided in the solicitation. The procurement will be conducted under FAR part 12 regulations, ensuring that all eligible sources may submit proposals for consideration. Interested parties can access the solicitation on the DLA Bid Board System (DIBBS) and SAM.gov, with the anticipated solicitation release expected around May 2026, though DLA reserves the right to adjust this timing. For inquiries, Courtney Hunter serves as the primary point of contact, and interested vendors are encouraged to set up automated notifications for any updates or changes regarding the solicitation. The contract's NAICS code is 325412, and it will be managed by the DLA Troop Support office located in Philadelphia, Pennsylvania.
General Info
Agency
NAICS
Place of Performance
PASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Pantoprazole DR Tablets. Procurement details follow.
Pantoprazole DR: 40 MG Tablets in 90 and 1000 Count Bottles and 20 MG Tablets in 90 Count Bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense customers through the DLA prime vendor program. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.
A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and SAM.gov at https://sam.gov. Interested parties should contact Courtney Hunter at (445) 737-3585 or Courtney.Hunter@dla.mil for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is May of 2026. DLA reserves the right to issue the solicitation before or after the projected solicitation date.